LYTIX
Euronext Growth Oslo
Biotechnology & Pharmaceuticals
Health Care
Lytix Biopharma is a clinical-stage biotechnology company developing cancer immunotherapies. The company's technology is based on research into antimicrobial peptides, a defense against pathogens. Lytix Biopharma's lead product, LTX-315, is an oncolytic peptide with the aim of personalizing immunotherapy. The company conducts its research and operations in Oslo, Norway.
Read moreInterim report Q3'26
Don't miss out - create an account and get all the possible benefits